CD79A and COVID-19: In this same study, we also saw that among Dengue patients recruited before COVID-19, in one of them (8.3%), anti-SARS-CoV-2 Spike 1 IgA was detected, and in none of them was anti-SARS-CoV-2 Spike 1 IgG detected, indicating that the commercial serological kits for COVID-19 used presented high specificity and sensitivity [14].